About Ribonucleoside-diphosphate reductase subunit M2
Ribonucleoside-diphosphate reductase subunit M2 (RRM2) is a protein
from Homo sapiens identified by UniProt accession
P31350, 389 residues long.
MolForge cross-references it against 0 known binders and
336 disease associations.
Target properties
| Protein name | Ribonucleoside-diphosphate reductase subunit M2 |
| UniProt accession | P31350 |
| Gene | RRM2 |
| Organism | Homo sapiens |
| Length | 389 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Approved drugs hitting this target (5)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (336)
Diseases linked to this target (Open Targets).
- sickle cell anemia · score 0.58
- melanoma · score 0.56
- neurodegenerative disease · score 0.53
- polycythemia vera · score 0.51
- essential thrombocythemia · score 0.50
- HIV infection · score 0.46
- chronic myelogenous leukemia · score 0.44
- neoplasm · score 0.41
- leukemia · score 0.39
- Thalassemia · score 0.39
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P31350-F1 | alphafold | PREDICTED | 79.71 | — |
Amino-acid sequence (389 residues)
MLSLRVPLAP ITDPQQLQLS PLKGLSLVDK ENTPPALSGT RVLASKTARR IFQEPTEPKT KAAAPGVEDE PLLRENPRRF VIFPIEYHDI WQMYKKAEAS FWTAEEVDLS KDIQHWESLK PEERYFISHV LAFFAASDGI VNENLVERFS QEVQITEARC FYGFQIAMEN IHSEMYSLLI DTYIKDPKER EFLFNAIETM PCVKKKADWA LRWIGDKEAT YGERVVAFAA VEGIFFSGSF ASIFWLKKRG LMPGLTFSNE LISRDEGLHC DFACLMFKHL VHKPSEERVR EIIINAVRIE QEFLTEALPV KLIGMNCTLM KQYIEFVADR LMLELGFSKV FRVENPFDFM ENISLEGKTN FFEKRVGEYQ RMGVMSSPTE NSFTLDADF
Explore Ribonucleoside-diphosphate reductase subunit M2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets